DBVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 37 of 42 cases where DBVT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DBVT's RSI Indicator exited the oversold zone, 24 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on DBVT as a result. In 67 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for DBVT just turned positive on October 20, 2026. Looking at past instances where DBVT's MACD turned positive, the stock continued to rise in 40 of 50 cases over the following month. The odds of a continued upward trend are 80%.
Following a +2.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where DBVT advanced for three days, in 161 of 202 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for DBVT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.790) is normal, around the industry mean (2.973). P/E Ratio (-2.766) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (75.432) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. DBVT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where GPCR advanced for three days, in 177 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 21 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Moving Average Convergence Divergence (MACD) for GPCR just turned positive on October 20, 2026. Looking at past instances where GPCR's MACD turned positive, the stock continued to rise in 29 of 37 cases over the following month. The odds of a continued upward trend are 78%.
GPCR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GPCR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for GPCR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.155) is normal, around the industry mean (2.973). P/E Ratio (-7.238) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. GPCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GPCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
DBVT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 15 | |
SEASONALITY SCORE 1..100 | 13 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| DBVT | GPCR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 65% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 85% | N/A |
| Momentum ODDS (%) | 1 day ago 74% | N/A |
| MACD ODDS (%) | 1 day ago 80% | 1 day ago 78% |
| TrendWeek ODDS (%) | 1 day ago 79% | 1 day ago 85% |
| TrendMonth ODDS (%) | 1 day ago 87% | 1 day ago 88% |
| Advances ODDS (%) | 1 day ago 80% | 3 days ago 85% |
| Declines ODDS (%) | 4 days ago 90% | 1 day ago 86% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 69% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DBVT’s FA Score shows that 1 FA rating(s) are green while GPCR’s FA Score has 2 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DBVT’s TA Score shows that 5 TA indicator(s) are bullish while GPCR’s TA Score has 4 bullish TA indicator(s).
DBVT (@Biotechnology) experienced а +6.26% price change this week, while GPCR (@Biotechnology) price change was -1.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
DBVT is expected to report earnings on Oct 27, 2026.
GPCR is expected to report earnings on Nov 05, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DBVT has been loosely correlated with KYMR. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if DBVT jumps, then KYMR could also see price increases.
| Ticker / NAME | Correlation To DBVT | 1D Price Change % | ||
|---|---|---|---|---|
| DBVT | 100% | +0.62% | ||
| KYMR - DBVT | 35% Loosely correlated | -1.58% | ||
| GPCR - DBVT | 35% Loosely correlated | -0.36% | ||
| CRDF - DBVT | 32% Poorly correlated | -1.17% | ||
| CGEN - DBVT | 31% Poorly correlated | -7.55% | ||
| OCUL - DBVT | 31% Poorly correlated | +2.01% | ||
More | ||||